Juliana C Garrido
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juliana C Garrido has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Clarice M Mata-Machado
Programa de Pós-Graduação em Saúde Aplicada às Ciências do Adulto, Universidade Federal de Minas Gerais (UFMG), Rheumatology Service, Hospital das Clínicas da UFMG/Ebserh , Belo Horizonte
1 shared publication - Cristina Costa Duarte Lanna
Departamento do Aparelho Locomotor, Faculdade de Medicina, Universidade Federal de Minas Gerais, Av. Prof. Alfredo Balena, 190, Santa Efigênia, Belo Horizonte 30130-100, MG, Brazil
1 shared publication - Evandro Mendes Klumb
Rheumatology Service, Hospital Universitário Pedro Ernesto (HUPE), Universidade do Estado do Rio de Janeiro (UERJ), Rio de Janeiro, Brazil
1 shared publication - Fabiana de Miranda Moura
Locomotor System Department - Medical School - Universidade Federal de Minas Gerais - Belo Horizonte (Minas Gerais) - Brazil, Avenida Professor Alfredo Balena, 190 - Santa Efigênia, Belo Horizonte, Minas Gerais, 30130-100, Brazil
1 shared publication - Guilherme L Tres
Division of Rheumatology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul , Porto Alegre
1 shared publication - Odirlei André Monticielo
Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre 90010-150, RS, Brazil
1 shared publication
Latest Publications
- 4 July 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (11) , 5811-5817
Validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) in Brazilian SLE patients
Objectives: To evaluate the measurement properties of SLE-DAS, using the Brazilian-Portuguese version (SLE-DAS Pt-BR). Methods: Cross-sectional, test-retest, multicentre study, that included patients ≥18 years old who met the classification criteria for SLE. Reliability was tested using type 2.1 intraclass correlation coefficient (ICC2.1), standard measurement error (SEM) and minimum detectable difference (MDD). For construct validity, Spearman correlation (rho) and/or percentage of agreement with χ2 test were used to correlate/associate SLE-DAS Pt-BR with SLEDAI-2K, PGA and the definitions of remission (DORIS) and low disease activity (LLDAS). Performance of SLE-DAS was assessed with PGA as reference standard, calculating sensitivity, specificity and accuracy. Results: A total of 365 patients were included: mean age 44.5 (SD 14.0) years, 92.9% female. 57.3% were in remission according to SLE-DAS Pt-BR. Excellent intra and inter-rater reliability was observed (ICC2.1 = 0.999 and 0.945, respectively), with acceptable SEM/MDD. There was a strong correlation between SLE-DAS Pt-BR with SLEDAI-2K (rho = 0.895) and PGA (rho = 0.861). Sensitivity, specificity and accuracy of SLE-DAS Pt-BR were above 90% for remission and moderate/severe disease activity and above 80% for mild activity. Most individuals in remission and in moderate/severe activity according to SLEDAI-2K were also in those categories according to SLE-DAS Pt-BR (99.5% and 77.9%, respectively). Considering mild activity concordance was observed in 42.9% patients. Most patients considered in DORIS remission and LLDAS were also in remission and in low disease activity by SLE-DAS Pt-BR. Conclusion: The present study demonstrated that the SLE-DAS Pt-BR is valid and capable of measuring SLE disease activity.
- 4 July 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (11) , 5811-5817
Validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) in Brazilian SLE patients
Objectives: To evaluate the measurement properties of SLE-DAS, using the Brazilian-Portuguese version (SLE-DAS Pt-BR). Methods: Cross-sectional, test-retest, multicentre study, that included patients ≥18 years old who met the classification criteria for SLE. Reliability was tested using type 2.1 intraclass correlation coefficient (ICC2.1), standard measurement error (SEM) and minimum detectable difference (MDD). For construct validity, Spearman correlation (rho) and/or percentage of agreement with χ2 test were used to correlate/associate SLE-DAS Pt-BR with SLEDAI-2K, PGA and the definitions of remission (DORIS) and low disease activity (LLDAS). Performance of SLE-DAS was assessed with PGA as reference standard, calculating sensitivity, specificity and accuracy. Results: A total of 365 patients were included: mean age 44.5 (SD 14.0) years, 92.9% female. 57.3% were in remission according to SLE-DAS Pt-BR. Excellent intra and inter-rater reliability was observed (ICC2.1 = 0.999 and 0.945, respectively), with acceptable SEM/MDD. There was a strong correlation between SLE-DAS Pt-BR with SLEDAI-2K (rho = 0.895) and PGA (rho = 0.861). Sensitivity, specificity and accuracy of SLE-DAS Pt-BR were above 90% for remission and moderate/severe disease activity and above 80% for mild activity. Most individuals in remission and in moderate/severe activity according to SLEDAI-2K were also in those categories according to SLE-DAS Pt-BR (99.5% and 77.9%, respectively). Considering mild activity concordance was observed in 42.9% patients. Most patients considered in DORIS remission and LLDAS were also in remission and in low disease activity by SLE-DAS Pt-BR. Conclusion: The present study demonstrated that the SLE-DAS Pt-BR is valid and capable of measuring SLE disease activity.